Prestige Consumer Healthcare Inc. (NYSE:PBH) Stock Position Lifted by Xponance Inc.

Xponance Inc. boosted its stake in Prestige Consumer Healthcare Inc. (NYSE:PBH) by 10.1% in the fourth quarter, Holdings Channel reports. The institutional investor owned 3,570 shares of the company’s stock after acquiring an additional 328 shares during the quarter. Xponance Inc.’s holdings in Prestige Consumer Healthcare were worth $279,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of PBH. Martingale Asset Management L P raised its holdings in shares of Prestige Consumer Healthcare by 0.4% during the third quarter. Martingale Asset Management L P now owns 36,971 shares of the company’s stock worth $2,666,000 after acquiring an additional 140 shares in the last quarter. QRG Capital Management Inc. increased its position in Prestige Consumer Healthcare by 3.3% in the 4th quarter. QRG Capital Management Inc. now owns 5,496 shares of the company’s stock worth $429,000 after purchasing an additional 176 shares during the last quarter. GAMMA Investing LLC raised its stake in shares of Prestige Consumer Healthcare by 18.9% during the 4th quarter. GAMMA Investing LLC now owns 1,383 shares of the company’s stock worth $108,000 after purchasing an additional 220 shares in the last quarter. PNC Financial Services Group Inc. lifted its holdings in shares of Prestige Consumer Healthcare by 5.9% during the 4th quarter. PNC Financial Services Group Inc. now owns 5,276 shares of the company’s stock valued at $412,000 after buying an additional 296 shares during the last quarter. Finally, Kestra Investment Management LLC bought a new stake in shares of Prestige Consumer Healthcare in the 4th quarter valued at approximately $27,000. Institutional investors and hedge funds own 99.95% of the company’s stock.

Prestige Consumer Healthcare Price Performance

NYSE PBH opened at $86.07 on Friday. The stock has a 50-day simple moving average of $83.17 and a 200 day simple moving average of $78.89. Prestige Consumer Healthcare Inc. has a twelve month low of $62.35 and a twelve month high of $90.04. The stock has a market capitalization of $4.26 billion, a PE ratio of 20.16, a P/E/G ratio of 2.69 and a beta of 0.46. The company has a debt-to-equity ratio of 0.56, a quick ratio of 2.20 and a current ratio of 3.68.

Prestige Consumer Healthcare (NYSE:PBH) last posted its quarterly earnings data on Thursday, February 6th. The company reported $1.22 earnings per share for the quarter, beating the consensus estimate of $1.18 by $0.04. Prestige Consumer Healthcare had a return on equity of 12.36% and a net margin of 19.13%. Research analysts anticipate that Prestige Consumer Healthcare Inc. will post 4.5 EPS for the current year.

Insiders Place Their Bets

In related news, SVP Mary Beth Fritz sold 1,678 shares of the stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $90.00, for a total value of $151,020.00. Following the completion of the sale, the senior vice president now owns 17,157 shares in the company, valued at approximately $1,544,130. This trade represents a 8.91 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 1.60% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on PBH. StockNews.com raised shares of Prestige Consumer Healthcare from a “hold” rating to a “buy” rating in a research report on Tuesday, March 18th. Oppenheimer raised their price target on shares of Prestige Consumer Healthcare from $87.00 to $93.00 and gave the company an “outperform” rating in a report on Thursday, February 13th. DA Davidson raised their target price on Prestige Consumer Healthcare from $95.00 to $104.00 and gave the company a “buy” rating in a report on Friday, February 7th. Raymond James upgraded Prestige Consumer Healthcare to a “moderate buy” rating in a research note on Thursday, December 19th. Finally, Sidoti downgraded Prestige Consumer Healthcare from a “buy” rating to a “neutral” rating and set a $90.00 price objective on the stock. in a research note on Monday, December 9th. Three research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $93.33.

Prestige Consumer Healthcare Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.